- Home
- UFCS vs CDXC Comparison
UFCS vs CDXC Comparison
Compare UFCS & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- CDXC
- Stock Information
- Founded
- UFCS 1946
- CDXC 1999
- Country
- UFCS United States
- CDXC United States
- Employees
- UFCS N/A
- CDXC N/A
- Industry
- UFCS Property-Casualty Insurers
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- UFCS Finance
- CDXC Health Care
- Exchange
- UFCS Nasdaq
- CDXC Nasdaq
- Market Cap
- UFCS 642.7M
- CDXC 572.6M
- IPO Year
- UFCS N/A
- CDXC N/A
- Fundamental
- Price
- UFCS $28.95
- CDXC $5.49
- Analyst Decision
- UFCS Hold
- CDXC Strong Buy
- Analyst Count
- UFCS 1
- CDXC 2
- Target Price
- UFCS $26.00
- CDXC $8.00
- AVG Volume (30 Days)
- UFCS 154.0K
- CDXC 751.0K
- Earning Date
- UFCS 02-11-2025
- CDXC 10-31-2024
- Dividend Yield
- UFCS 2.21%
- CDXC N/A
- EPS Growth
- UFCS N/A
- CDXC N/A
- EPS
- UFCS 1.94
- CDXC 0.02
- Revenue
- UFCS $1,207,451,000.00
- CDXC $91,668,000.00
- Revenue This Year
- UFCS N/A
- CDXC $18.64
- Revenue Next Year
- UFCS $11.31
- CDXC $20.72
- P/E Ratio
- UFCS $14.90
- CDXC $279.02
- Revenue Growth
- UFCS 10.95
- CDXC 9.95
- 52 Week Low
- UFCS $18.04
- CDXC $1.36
- 52 Week High
- UFCS $31.70
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- UFCS 50.15
- CDXC 33.96
- Support Level
- UFCS $30.11
- CDXC $6.55
- Resistance Level
- UFCS $31.35
- CDXC $7.79
- Average True Range (ATR)
- UFCS 0.92
- CDXC 0.38
- MACD
- UFCS -0.54
- CDXC -0.26
- Stochastic Oscillator
- UFCS 8.33
- CDXC 9.45
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.